Cypress, California Clinical Trials

A listing of Cypress, California clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 52 clinical trials
Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor SAR442168 (PERSEUS)

Primary Objective: To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in primary progressive multiple sclerosis (PPMS) Secondary Objectives: To evaluate efficacy of SAR442168 compared to placebo on clinical endpoints, magnetic resonance imaging (MRI) lesions, cognitive performance, physical function, and quality of life To evaluate safety …

oligoclonal bands
Investigational Site Number 8400045
 (8.9 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +14 other locations
Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B With or Without Inhibitory Antibodies to Factor VIII or IX

Primary Objective: To characterize the long-term safety and tolerability of fitusiran Secondary Objectives: To characterize the long-term efficacy of fitusiran as assessed by the frequency of: Bleeding episodes Spontaneous bleeding episodes Target joint bleeding episodes To characterize the effects of fitusiran on health-related quality of life (HRQOL) measures in participants …

antihemophilic factor
haemophilia a
hemophilia
hemarthrosis
fitusiran
Investigational Site Number 8400016
 (9.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +43 other locations
Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

Primary Objective: To confirm appropriate dose levels of fitusiran when administered to male pediatric participants (ages 1 to <12 years of age) with severe hemophilia A or B Secondary Objective: To characterize the safety and tolerability To characterize the pharmacokinetics (PK)

antihemophilic factor
factor ix
haemophilia a
bethesda assay
hemophilia
Investigational Site Number 8400010
 (9.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +10 other locations
A Study to Evaluate the Efficacy and Safety of Frexalimab, SAR442970, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease (RESULT)

This is a parallel, Phase 2a, double-blind, 6-arm study for the treatment of primary focal segmental glomerulosclerosis (FSGS) or primary minimal change disease (MCD).The purpose of this study is to measure the change in proteinuria and its impact on the rates of remission of nephrotic syndrome with frexalimab, SAR442970, or …

Investigational Site Number : 8400015
 (9.5 away) Contact site
  • 0 views
  • 20 Jun, 2025
  • +24 other locations
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.

headache
ly573144
migraine
preventive medication
lasmiditan
Core Healthcare Group
 (4.0 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +162 other locations
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

This is a Phase 3, multi-center, randomized, open-label, controlled study designed to evaluate the safety and efficacy of cabozantinib given in combination with atezolizumab versus a second novel hormonal therapy (NHT) in men with metastatic castration-resistant prostate cancer (mCRPC) who have previously been treated with one, and only one, NHT …

soft tissue disease
atezolizumab
medical castration
hormonal therapy
prostate adenocarcinoma
Exelixis Clinical Site #2
 (8.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +1 other locations
A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression

Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. It is the most common form of lung cancer, accounting for around 85% of lung cancers. The purpose of this study is to evaluate the safety and efficacy …

measurable disease
solid tumor
epidermal growth factor receptor
stage iv non-small cell lung cancer
drug test
Icri /Id# 217071
 (9.1 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +38 other locations
A Study of LY3372993 in Participants With Alzheimer's Disease (AD)

The main purpose of this study is to evaluate the safety and tolerability of LY3372993 in participants with AD. The study will also investigate how much LY3372993 gets into the bloodstream and will test the effects of LY3372993. Participation could last up to about 54 weeks and may include up …

mini-mental state examination
cognitive impairment
mental state examination
dementia
alzheimer's disease
Collaborative Neuroscience Network - CNS
 (8.9 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +6 other locations
Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne

The purpose of the trial is to evaluate the safety, efficacy and immunogenicity of up to 3 intramuscular injections of the Acne mRNA vaccine candidate at up to three dose levels in adult participants aged 18 to 45 years with moderate to severe acne. This trial will consist of a …

Core Healthcare Group- Site Number : 8400067
 (4.0 away) Contact site
  • 0 views
  • 29 Nov, 2025
  • +30 other locations
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of AB928-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).

prostatic neoplasm
measurable disease
prostatic neoplasms, castration-resistant
combined modality therapy
docetaxel
The Oncology Institute of Hope & Innovation
 (9.1 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +21 other locations